Romina Lenci

Life Sciences Strategy Consultant & SME in Translational Genomics, Biomarkers, and Precision Medicine

About

Ph.D.-level Life Sciences Strategy Consultant and Subject Matter Expert specializing in translational genomics, biomarker-driven assays, and precision medicine. Advises biotech, pharma, and investment teams on technology evaluation, R&D prioritization, competitive intelligence, and portfolio strategy. Extensive experience with NGS workflows, cfDNA and tissue assays, multi-omics analysis, and regulatory-aligned development, translating complex molecular and clinical data into actionable insights for strategic decision-making. Collaborates with clients to identify emerging biomarker trends, evaluate technologies, and inform innovation strategies, bridging scientific innovation and business impact. Available for expert insights calls, technical due diligence, landscape analyses, and collaborative projects requiring deep expertise in translational genomics, molecular diagnostics, and precision medicine.

Education

Ruprecht-Karls-Universitt Heidelberg Germany

Ph.D.

University of Buenos Aires Argentina

Biochemist (6-year degree)

Experience

Independent Consultant

Independent Genomics Oncology Consultant / July, 2022 — Present

Advise global consulting firms and expert networks (GLG Dialectica Guidepoint Tegus etc.) on NGS technologies cfDNA workflows oncology biomarkers and precision medicine strategies. Conduct technical diligence competitive intelligence and market assessments to inform investment and strategic decision-making for biotech and diagnostic platforms. Translate complex scientific and clinical data into actionable insights for investors and strategic teams including RD prioritization platform evaluation and technology differentiation. Provide guidance on emerging early-stage diagnostic technologies including biomarker trends assay feasibility and platform positioning within competitive landscapes. Bridge scientific innovation and business strategy by highlighting clinically meaningful endpoints assay considerations and translational opportunities.

Harbinger Health

Principal Scientist / October, 2023 — August, 2025

Senior scientific lead for a diagnostic-grade cfDNA methylation assay with strong exposure to strategy competitive intelligence and regulatory alignment. Led clinical NGS assay development in a CLIACAPNYS-regulated environment with RD aligned to diagnostic product requirements. Supported FDA-readiness efforts by reviewing FDA-approved liquid biopsy assays (Cologuard Guardant360 CDx Shield FoundationOne Liquid CDx) analyzing SSEDs and translating benchmarks into internal guidance. Conducted analytical validation-style studies (miniaturization reproducibility cost optimization) reducing per-sample costs by 27 and improving workflow scalability. Led competitive intelligence and landscape analysis evaluating technologies and products from Natera GRAIL Guardant Health Tempus Exact Sciences and Foundation Medicine. Delivered conference intelligence and market surveillance synthesizing insights into executive-ready summaries informing product positioning and innovation strategy. Collaborated cross-functionally with data science product and leadership teams to prioritize biomarker targets and guide portfolio decisions. Evaluated emerging technologies and publications for technical feasibility commercial readiness and strategic fit informing RD and product strategy. Initiated and led external collaborations with biotech companies and academic partners to access pre-commercial technologies and improve assay performance (50% cfDNA recovery improvement).

Columbia University

Associate Director Next Generation Sequencing / January, 2021 — May, 2022

Directed large-scale Illumina sequencing operations supporting clinical and translational research programs. Optimized WESWGS workflows significantly reducing DNA input requirements while maintaining data quality. Managed technical workflows and cross-functional interactions ensuring quality efficiency and stakeholder alignment.

Associate Research Scientist / January, 2019 — December, 2020

Led translational epigenetics research in breast cancer integrating multi-omics data to support biomarker discovery. Designed and executed ChIP-seq RNA-seq and ATAC-seq studies; mentored junior scientists.

Dana-Farber Cancer Institute, Harvard Medical School

Postdoctoral Research Fellow / September, 2013 — May, 2017

Applied high-throughput epigenomics to cancer genetics and regulatory mechanisms across multiple tumor types. Developed allele-specific assays and contributed to insights relevant to disease progression and therapy.

Join Romina on NotedSource!

Join Now

At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.

For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.

For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.